Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease

Esophageal involvement in Crohn’s disease is rare. We present a case of refractory esophageal Crohn’s disease that responded to ustekinumab, which has shown promise in the treatment of refractory, typically intestinal Crohn’s disease. There are no prior reports on the successful use of ustekinumab i...

Descripción completa

Detalles Bibliográficos
Autores principales: Barkin, Jodie A., Deshpande, Amar R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748197/
https://www.ncbi.nlm.nih.gov/pubmed/26958561
http://dx.doi.org/10.14309/crj.2016.15
_version_ 1782415080135065600
author Barkin, Jodie A.
Deshpande, Amar R.
author_facet Barkin, Jodie A.
Deshpande, Amar R.
author_sort Barkin, Jodie A.
collection PubMed
description Esophageal involvement in Crohn’s disease is rare. We present a case of refractory esophageal Crohn’s disease that responded to ustekinumab, which has shown promise in the treatment of refractory, typically intestinal Crohn’s disease. There are no prior reports on the successful use of ustekinumab in esophageal Crohn’s disease, but should be considered as a possible management strategy in patients with this condition.
format Online
Article
Text
id pubmed-4748197
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher American College of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-47481972016-03-08 Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease Barkin, Jodie A. Deshpande, Amar R. ACG Case Rep J Case Report Esophageal involvement in Crohn’s disease is rare. We present a case of refractory esophageal Crohn’s disease that responded to ustekinumab, which has shown promise in the treatment of refractory, typically intestinal Crohn’s disease. There are no prior reports on the successful use of ustekinumab in esophageal Crohn’s disease, but should be considered as a possible management strategy in patients with this condition. American College of Gastroenterology 2016-01-20 /pmc/articles/PMC4748197/ /pubmed/26958561 http://dx.doi.org/10.14309/crj.2016.15 Text en Copyright © Barkin et al. This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Case Report
Barkin, Jodie A.
Deshpande, Amar R.
Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
title Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
title_full Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
title_fullStr Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
title_full_unstemmed Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
title_short Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
title_sort ustekinumab for successful treatment of refractory esophageal crohn’s disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748197/
https://www.ncbi.nlm.nih.gov/pubmed/26958561
http://dx.doi.org/10.14309/crj.2016.15
work_keys_str_mv AT barkinjodiea ustekinumabforsuccessfultreatmentofrefractoryesophagealcrohnsdisease
AT deshpandeamarr ustekinumabforsuccessfultreatmentofrefractoryesophagealcrohnsdisease

Ejemplares similares